Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocugen, Inc. - Common Stock
(NQ:
OCGN
)
1.990
+0.060 (+3.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen, Inc. - Common Stock
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
35
36
Next >
Ocugen Is a Strong Sell, Vaccine Unlikely to Find Commercial Success
↗
October 15, 2021
Still, traders haven't given up; despite a mountain of bad news, OCGN stock inexplicably trades for nearly $10 per share.
Via
InvestorPlace
Topics
Lawsuit
Why Ocugen Stock Is Skyrocketing This Week
↗
October 15, 2021
Positive developments for COVID-19 vaccine Covaxin appear to have kicked off a short squeeze.
Via
The Motley Fool
OCGN Stock: One Big Reason Why Ocugen Is Climbing Today
↗
October 14, 2021
Covid-19 vaccine play Ocugen is seeing impressive investor interest today, with OCGN stock seeing double-digit gains at the time of writing.
Via
InvestorPlace
Ocugen Stock Needs a Catalyst for Growth That Probably Isn’t Coming
↗
October 13, 2021
InvestorPlace’s Louis Navellier believes all Ocugen needs is a catalyst. OCGN stock got two. Its share price barely moved.
Via
InvestorPlace
45 Biggest Movers From Yesterday
↗
October 13, 2021
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on...
Via
Benzinga
Is This Going To Be The Next Big Factor For Ocugen (OCGN) Stock?
↗
October 13, 2021
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 18.5% in Tuesday’s regular trading session, extending gains to a second straight day. What...
Via
Benzinga
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up
↗
October 12, 2021
Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesd...
Via
Benzinga
Most Active Equity Options For Midday - Tuesday, Oct. 12
↗
October 12, 2021
Top Tickers: TSLA, AAPL, FB, F, T, MU, PROG, SOFI, FCX, BABA, BBIG, WKHS, OCGN, NVDA, AMC, AMD, MGM, BAC, AMZN, NIO.
Via
Talk Markets
Benchmarks Muted After Slashed Global Growth Forecast
↗
October 12, 2021
The major indexes are struggling for direction this afternoon after fresh data from the U.S. Labor Department showed job openings in August fell sharply to 10.4 million, while workers quit retail and...
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 12, 2021
Gainers NRX Pharmaceuticals (NASDAQ:NRXP...
Via
Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
↗
October 12, 2021
Gainers ESS Tech Inc (NYSE: GWH) shares jumped 96.4% to $20.46. ESS Inc, the Bill Gates-backed battery maker went public on the New York Stock Exchange on Monday after...
Via
Benzinga
OCGN Stock: One Big Reason Ocugen Is Powering Higher Today
↗
October 12, 2021
OCGN stock is making its investors quite happy this morning and prompting many more to pile in. The company is receiving crucial approval.
Via
InvestorPlace
Why Ocugen Stock Is on Fire Today
↗
October 12, 2021
A positive regulatory development in India is sending the biotech's shares higher today.
Via
The Motley Fool
Why Ocugen's Stock Is Trading Higher Today
↗
October 12, 2021
Ocugen Inc (NASDAQ: OCGN) is trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine, Covaxin, for children between the age of...
Via
Benzinga
Ocugen Will Have Value If Its Covid Vaccine Can Get Approved
↗
October 12, 2021
OCGN stock could be at a full value today given revenue prospects but could still rise if its Covaxin vaccine gains approval outside India.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 12, 2021
Gainers Viridian Therapeutics (NASDAQ:VRDN) stock rose 22.49% to $19.17 during Tuesday's pre-market session. The company's market cap stands at $331.8 million. Inhibrx (...
Via
Benzinga
15 Stocks Moving in Tuesday's Pre-Market Session
↗
October 12, 2021
Gainers Quanterix Corporation (NASDAQ: QTRX) shares rose 17.6% to $48.55 in pre-market trading after the company announced its Simoa phospho-Tau 181 blood test has been granted...
Via
Benzinga
Don’t Buy Too Much Into the WHO Hype Surrounding Ocugen Stock
↗
October 12, 2021
The latest buzz around Covaxin does little to improve the prospects of OCGN stock, so buying it for this reason doesn't make much sense.
Via
InvestorPlace
Why Did Ocugen Stock Skyrocket On Monday?
↗
October 12, 2021
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session. What...
Via
Benzinga
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN
October 08, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
WHO To Finalize Nod To Ocugen-Partnered Covaxin Next Week: Sources
↗
October 05, 2021
The World Health Organization said a decision on the Emergency Use Listing (EUL) of India's COVID-19 vaccine, Covaxin, will be finalized next week. Ocugen Inc (...
Via
Benzinga
Ocugen Bulls Are Overlooking Its FDA Approval Hurdles
↗
October 05, 2021
The FDA seems highly unlikely to approve the Covaxin vaccine, making OCGN stock an excellent name to short going forward.
Via
InvestorPlace
OCGN Stock: 2 Huge Reasons Ocugen Stock Is Shooting Higher Today
↗
October 05, 2021
OCGN stock is surging on some big news. The World Health Organization could give the company the go-ahead on its Covid-19 vaccine very soon.
Via
InvestorPlace
Why Ocugen Shares Are Trading Higher Today
↗
October 05, 2021
Ocugen Inc (NASDAQ: OCGN) is trading higher Tuesday after a company 8-K showed it entered into a Development and Commercial Supply Agreement with Bharat Biotech pursuant to...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 05, 2021
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4...
Via
Benzinga
WHO Approval Won’t Move Ocugen Stock Very Much Over the Long Term
↗
October 05, 2021
The WHO's nod of approval wont be fruitful to OCGN stock in blowing past the regulatory hurdles in the North American Covid 19 vaccine market.
Via
InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
↗
October 05, 2021
Gainers Marine Petroleum Trust (NASDAQ: MARPS) rose 25.4% to $6.29 in pre-market trading after gaining 8% on Monday. Agrify Corporation. (NASDAQ: AGFY) rose 17.8% to $21.76 in...
Via
Benzinga
WHO To Decide On EUL Of Ocugen-Partnered COVID-19 Vaccine Today
↗
October 05, 2021
An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today. Covaxin is India's indigenously-...
Via
Benzinga
Ocugen Stock Just Needs a Catalyst to Break Free
↗
October 04, 2021
OCGN stock holders should be patient as the World Health Organization's potential approval of an important vaccine could happen soon.
Via
InvestorPlace
It’s Time To Drop Ocugen Stock While You Still Can
↗
October 04, 2021
Hope is one thing, but for OCGN stock investors expecting regulators or other bulls to come to the rescue, things are starting to look gloomy.
Via
InvestorPlace
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.